Sign in to fuzzto save your conversations, follow your research and come back anytime.
In the news
Manipal Health Gets ₹825 Target Price on Acquisition Strategy
Manipal Health repays ₹5,310 cr debt using IPO proceeds
Manipal Health Gets 'Buy' Ratings; Expands Acquisition Strategy
Manipal Health Crosses ₹1 Trillion Market Cap, HSBC Sees 26% Upside
Manipal Health Q1 profit drops 7.48% to ₹232 cr despite 38% revenue growth
Company insights, generated from the most recent coverage.
Manipal's FY23-FY26 revenue CAGR of 28.8% with EBITDA margins held at 25-27% shows it scaled fast without sacrificing profitability — operational discipline behind Temasek's return.
Temasek's Manipal entry at $1.14B (2017) re-rated above $4B by 2022 as scale grew from 15 to 49 hospitals; TPG's ₹900 Cr (2015) also exited multi-fold — early platform bets compound via consolidation.
Manipal's FY25 ROE of 18.16% leads listed peers (Apollo 17.61%, Max 11.47%, Fortis 8.68%), reflecting superior capital returns in the hospital cohort.